During the 30th anniversary CPhI Worldwide exhibition, BIOCAD employees held more than 60 meetings with representatives of the pharmaceutical industry in Europe, China, the Middle East, North Africa, Asia and Latin America.

At a large-scale international venue that brought together more than 60 000 people from all over the world, BIOCAD introduced two new original drugs based on monoclonal antibodies - an interleukin-17 inhibitor (inn - netakimab) and a PD-1 inhibitor (inn - progolimab).

Netakimab was registered under the trade name Efleira in Russia for the treatment of psoriasis in April 2019, and in July it was already approved by the commission of the Ministry of Health of the Russian Federation for inclusion in the essential drug list (EDL).

Also at the CPhI BIOCAD publicly announced plans to introduce netakimab and prololimab to the European market and start of the clinical trials in Europe.

The company has already received permission to conduct an international multicenter, randomized, double-blind, placebo-controlled clinical trial of prololimab for non-small cell lung cancer in Slovakia and Hungary.

The study will include at least 292 patients who will be recruited within a period of 12 months in European Union, Russian Federation, and China.

The text above is a summary, you can read full article here.